Triamcinolone
| Evidence Level: L4 | Predicted Indications: 8 |
Table of Contents
Triamcinolone: Alopecia mucinosa
One-Sentence Summary
Triamcinolone is a corticosteroid, originally used for autoimmune and inflammatory conditions such as Crohn disease, adrenocortical insufficiency and acute lymphoblastic leukaemia. The TxGNN model predicts it may be effective for alopecia mucinosa (follicular mucinosis), but there are no registered clinical trials and only 2 publications (both case reports, neither testing triamcinolone directly).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Alopecia mucinosa |
| TxGNN Prediction Score | 0.9999 |
| Evidence Level | L4 |
| Canada Market Status | Marketed (marketed DINs: 16 of 16) |
| Number of DINs | 16 (marketed: 16) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, triamcinolone is a corticosteroid with established anti-inflammatory and immunosuppressive use across many autoimmune and inflammatory diseases, and mechanistically it may be applicable to inflammatory skin conditions.
Follicular mucinosis involves inflammatory cell infiltration around hair follicles together with mucin deposition. Because of this inflammatory component, intralesional triamcinolone is a plausible option, and corticosteroids are commonly used for localized lesions.
The supporting literature is weak, however. It consists of a 1964 case description and a 2014 case treated with topical bexarotene gel. Neither evaluates triamcinolone. The prediction is therefore a reasonable hypothesis rather than a demonstrated effect.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 23968145 | 2014 | Case report | International Journal of Dermatology | Idiopathic follicular mucinosis, with no association with cutaneous T-cell lymphoma, was successfully treated with topical bexarotene 1% gel. No uniformly effective therapy exists. Triamcinolone was not evaluated. |
| 14170262 | 1964 | Case report | Hifuka Kiyo. Acta Dermatologica | Case description of alopecia mucinosa Pinkus (mucinosis follicularis Jablonska). No abstract available. |
Canada Market Information
Triamcinolone has 16 valid licences in Canada and none cancelled. The data compiled for this report do not include dosage forms or approved indication text. The five licences below are listed by product name only.
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02437635 | APO-TRIAMCINOLONE AQ | Not specified | Not specified |
| 02194066 | ARISTOCORT C | Not specified | Not specified |
| 01999761 | KENALOG-10 INJECTION | Not specified | Not specified |
| 01999869 | KENALOG-40 INJECTION | Not specified | Not specified |
| 02368676 | TRIESENCE | Not specified | Not specified |
The remaining licences include topical products (e.g. TRIADERM, VIADERM KC, THERADERM), nasal sprays (NASACORT AQ, NASACORT ALLERGY 24HR) and others.
Safety Considerations
Contraindication signals from the knowledge graph (not label text): The knowledge graph links triamcinolone to the following conditions as contraindications:
- Cardiovascular and metabolic: hypertension, congestive heart failure, hyperglycaemia
- Infections: measles, herpes simplex virus keratitis
- Other: epilepsy, liver disease, gallbladder disease, urea cycle disorders (carbamoyl phosphate synthetase I deficiency, hyperargininemia, citrullinemia)
- Pituitary and endocrine: hypopituitarism, growth hormone deficiency and related hypogonadotropic hypogonadism or Kallmann syndrome
Drug Interactions: The interaction query returned 100 records. Examples from the first 20 reviewed:
- Major: adalimumab
- Moderate: zidovudine, isotretinoin, acarbose, acebutolol, acetazolamide, ketorolac, nifedipine, ibuprofen, ethinylestradiol, butalbital, albiglutide, aldesleukin, alefacept, alemtuzumab, aliskiren, tetanus toxoid vaccine, abametapir (topical)
- Minor: formoterol, salbutamol
Please refer to the package insert for full warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is very high (0.9999), but there are no clinical trials, and the only literature is two case reports that do not test triamcinolone. The mechanistic link is plausible but unproven, and it rests on general corticosteroid use rather than disease-specific evidence.
To proceed, the following is needed:
- Case series or trials of intralesional or topical triamcinolone in follicular mucinosis
- Mechanism of action data and package insert warnings and contraindications from Health Canada
- Dosage form and approved indication details for the Canadian licences, to confirm which routes are available (intralesional or topical)
Other predictions to consider: among the other predicted indications, Quinquaud’s folliculitis decalvans (evidence level L3, retrospective review of 23 patients and case-level reports) has somewhat stronger supporting evidence, though it also lacks triamcinolone-specific outcome data.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.